Dispositions, Real Property Held for Sale and Impairment (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Discontinued Operations and Disposal Groups [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Real Property Disposition Activity | The following is a summary of our real property disposition activity for the periods presented (in thousands):
(1) The nine months ended September 30, 2026 includes the disposition of three unconsolidated equity method investments that collectively owned 22 Outpatient Medical properties. The nine months ended September 30, 2025 includes the disposition of unconsolidated equity method investments related to our Chartwell joint ventures. See disclosure below for further information. (2) The nine months ended September 30, 2026 include $444,773,000 related to 28 properties classified as sales-type leases as of December 31, 2025 for which the underlying properties were sold and the sales-type leases terminated. The nine months ended September 30, 2025 include $172,260,000 related to four properties classified as sales-type leases as of December 31, 2024 for which the underlying properties were sold and the sales-type leases terminated. (3) The nine months ended September 30, 2026 exclude the net loss recognized in conjunction with the initial consolidation of variable interest entities and include a $3,059,000 loss for 28 properties classified as sales-type leases as of December 31, 2025 which were sold in 2026. The nine months ended September 30, 2025 include a $2,523,000 gain recognized for four properties classified as sales-type leases as of December 31, 2024 which were sold in 2025. (4) Non-cash consideration for the nine months ended September 30, 2026 relates primarily to the retained preferred interest for our Outpatient Medical portfolio disposition. Non-cash consideration for the nine months ended September 30, 2025 includes the fair value of the equity method investment attributed to the 16 sold Chartwell properties, the value of our contribution of ten consolidated properties to the Fund (see Note 8 for further details) and the deferred consideration in lieu of cash consideration for the acquired assets classified as held for sale and sold contemporaneously with the related acquisition.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||